September 3, 2015 9:15am
The primary endpoint for the ADRESU trial will be the number of patients who experience reduction of urinary leakage volume (as measured by the weight of diaper pads used over 24 hours) 52 weeks after treatment. CYTX closed at $0.35 and is UP +$0.02 or +4.61% on 12 K share volume in the premarket
Members only. Please login.